Radiotherapy (RT) Patterns of Care Study (PCS) in Lung Carcinoma

Reviewer: William Levin, MD
OncoLink
Last Modified: October 9, 2002

Share article


Presenter: B. Movsas
Presenter's Affiliation: Fox Chase Cancer Center (FCCC), Phila, PA, USA
Type of Session: Scientific

Background

  • This study was designed to determine the national patterns of radiation therapy (RT) practice in patients treated for non-metastatic lung cancer between 1998-1999.

Materials and Methods

  • A survey of randomly selected RT institutions was conducted. Both academic and non-academic institutions were surveyed.
  • Patients with non-metastatic lung cancer who received RT as definitive or adjuvant therapy were randomly selected.
  • The charts of 541 patients were reviewed.
  • 58 institutions were represented.

Results

  • 14.5% of histologies were small cell lung cancer (SCLC), while the remainder were non-small cell lung cancer (NSCLC).
  • Median age was 67 years (37-92).
  • 58% of patients were male, while 42% were female.
  • 32% of patients were current smokers.
  • 59% of patients had co-morbidities, mostly cardiopulmonary.
  • KPS was >80 in 84% of patients.
  • 98% of patients had staging CT scans.
  • In CS III patients, bone scans and brain MRI's were not obtained in 33% and 52%, respectively.
  • For NSCLC, a breakdown by clinical stage (CS) is as follows: CS I-12%, CS II-16%, CS III-54% (4% unknown).
  • For patients with NSCLC, 31% had their mediastinums pathologically staged.
  • Treatment strategies varied significantly by histology and stage.
  • The majority of patients with SCLC and stage III NSCLCA received chemotherapy (CT) + RT.
  • Most patients with CS I NSCLC received RT as their only treatment.
  • Median dose for RT in the SCLC patients was 51 Gy, 80% at 1.8-2 Gy/fraction; 10% received hyperfractionated (b.i.d.) RT.
  • 23% of these patients received prophylactic cranial irradiation (median dose, 30 Gy/15 fractions).
  • For NSCLC, the median dose was 60 Gy, 85% @ 1.8-2 Gy/fraction.
  • The majority of patients were treated with 6MV or 10 MV photons.
  • CT-based treatment planning was used in 50% of patients.
  • Maximum spinal cord dose was 41 Gy, although the dose was unknown in 29%.
  • 57% of patients received systemic treatment.
  • Surgery was performed in 28% of NSCLC patients.
  • 5% of all patients were enrolled on cooperative trials, and 2% on institutional (IRB-approved) trials.

Author's Conclusions

  • This study establishes the general patterns of care for lung cancer in U.S. RT facilities.
  • Better staging and documentation of spinal cord dose should be encouraged.

Clinical/Scientific Implications

  • The authors point out recent studies supporting the use of PCI and b.i.d. RT in SCLC have not had enough time to fully be reflected in a patterns of care study.
  • Also, this study reveals that a small percentage of lung cancer patients are being enrolled on clinical trials.

Oncolink's ASTRO Coverage made possible by an unrestricted Educational Grant from Ortho Biotech.


News
ASTRO: Cisplatin Plus RT, HDRB Beneficial for Cervical Cancer

Oct 4, 2013 - For women with stage IIIB squamous cervical cancer, cisplatin added to radiotherapy plus high-dose-rate brachytherapy is associated with improved disease-free survival, according to a study presented at the annual meeting of the American Society for Radiation Oncology, held from Sept. 22 to 25 in Atlanta.



I Wish You Knew

How cancer patients have changed my life

View More



Blogs and Web Chats

OncoLink Blogs give our readers a chance to react to and comment on key cancer news topics and provides a forum for OncoLink Experts and readers to share opinions and learn from each other.




OncoLink OncoPilot

Facing a new cancer diagnosis or changing the course of your current treatment? Let our cancer nurses help you through!

Learn More